A new Kayvirus vB_SauM-MUHD-1 combats Methicillin-resistant Staphylococcus aureus wound infections
Applied Microbiology and Biotechnology · 26.06.2026 · 110 (1)
DOI: 10.1007/s00253-026-13898-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 26.06.2026. Verfasst von Maha Kabil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology & Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcus Phages, Wound Infection, Phage Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mansoura University.
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA), a leading cause of chronic and post-surgical wound infections, is a hard-to-treat pathogen. In this study, we isolated and characterized a lytic MRSA bacteriophage, vB_SauM-MUHD-1, and evaluated its therapeutic potential in a murine wound infection model. Among 107 clinical wound samples, MRSA was reported in 48.6% of cases. Phage vB_SauM-MUHD-1, isolated from sewage, demonstrated lytic activity against 70.6% of the tested MRSA isolates. The phage exhibited efficient replication kinetics and remained stable under physiologically relevant conditions. Whole-genome sequencing identified a ~ 134 kb dsDNA genome (~ 30.45% GC) lacking detectable lysogeny-associated, virulence, or antimicrobial-resistance genes. In a BALB/c excisional wound model infected with MRSA, topical phage treatment significantly reduced bacterial burden, accelerated wound closure, and improved clinical severity scores compared to untreated controls, performing comparably to phage-linezolid combination therapy and outperforming linezolid monotherapy in bacterial clearance. These findings support that our phage vB_SauM-MUHD-1 has potential for treating MRSA-infected wounds and should be further investigated for efficacy in more challenging chronic or biofilm-rich wound environments. Key Points • This study provides a newly kayvirus, strictly lytic anti-MRSA phage vB_SauM-MUHD-1. • Phage exhibited favorable replication kinetics, physical stability and genomic safety. • Topical phage therapy reduced bacterial burden and accelerated wound healing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology & Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Botany Department, Faculty of Science, Mansoura University, Mansoura, Egypt. mohamed_4abdelmotelb@mans.edu.eg.
Förderung
- Mansoura University
Zitieren
APA
Kabil, M., El-Khier, N. T. A., Mowafy, W., El-Aziz, A. M. A., & Abdelmoteleb, M. (2026). A new Kayvirus vB_SauM-MUHD-1 combats Methicillin-resistant Staphylococcus aureus wound infections. Applied Microbiology and Biotechnology, 110(1). https://doi.org/10.1007/s00253-026-13898-8
Vancouver
Kabil M, El-Khier NTA, Mowafy W, El-Aziz AMA, Abdelmoteleb M. A new Kayvirus vB_SauM-MUHD-1 combats Methicillin-resistant Staphylococcus aureus wound infections. Applied Microbiology and Biotechnology. 2026;110(1). doi:10.1007/s00253-026-13898-8
BibTeX
@article{Kabil2026,
author = {Kabil, Maha and El-Khier, Noha T Abou and Mowafy, Wafaa and El-Aziz, Abeer M Abd and Abdelmoteleb, Mohamed},
title = {A new Kayvirus vB_SauM-MUHD-1 combats Methicillin-resistant Staphylococcus aureus wound infections},
journal = {Applied Microbiology and Biotechnology},
year = {2026},
volume = {110},
number = {1},
doi = {10.1007/s00253-026-13898-8}
}
EUVIMED